Search
Talphera Inc
TLPHAdd to Watchlist
1.070USD
+0.020+1.90%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
53.55MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.90%
5 Days
+3.88%
1 Month
+33.75%
6 Months
-7.76%
Year to Date
-6.14%
1 Year
+137.25%
Key Figures
1.050Open
1.100High
427.10KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.85%Turnover Ratio
1.050Prev. Close
1.030Low
254.07KTurnover
LossP/E Static
2.90P/B
0.00%Div Yield TTM
-63.14%ROA
1.57052wk High
2.48Volume Ratio
-13.00MNet Profit
50.05MShares
-0.2748EPS TTM
0.77Beta
-118.40%ROE
0.38052wk Low
6.67%Amplitude
100.00%Gross Margin
53.55MMarket Cap
5.66Reward/Risk
5.52%Risk Rate
TradingKey Stock Score of Talphera Inc
Currency: USD Updated: 2026-07-02Key Insights
Talphera Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 95 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.50.In the medium term, the stock price is expected to trend up.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Talphera Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Talphera Inc Highlights
StrengthsRisks
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.00K.
Undervalued
The company’s latest PE is -3.89, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 20.36M shares, increasing 3.54% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
3.500
Target Price
+233.33%
Upside Space
Talphera Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Talphera Inc Info
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Ticker SymbolTLPH
CompanyTalphera Inc
CEOAngotti (Vincent J)
Websitehttps://talphera.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Talphera Inc (TLPH)?
The current price of Talphera Inc (TLPH) is 1.07.
What is the symbol of Talphera Inc?
The ticker symbol of Talphera Inc is TLPH.
What is the 52-week high of Talphera Inc?
The 52-week high of Talphera Inc is 1.57.
What is the 52-week low of Talphera Inc?
The 52-week low of Talphera Inc is 0.38.
What is the market capitalization of Talphera Inc?
The market capitalization of Talphera Inc is 53.55M.
Is Talphera Inc (TLPH) currently rated as Buy, Hold, or Sell?
According to analysts, Talphera Inc (TLPH) has an overall rating of Buy, with a price target of 3.50.
What is the Earnings Per Share (EPS TTM) of Talphera Inc (TLPH)?
The Earnings Per Share (EPS TTM) of Talphera Inc (TLPH) is -0.34.